Search results
Jul 16, 2024 · SOTIO Biotech Inc. 180 Canal St, Suite 300 Boston, MA 02114 USA CONTACT. Prague Prague. SOTIO Biotech a.s. Českomoravská 2532/19b 190 00 Prague 9 Czech Republic ...
- About us
The Company. SOTIO Biotech is shaping the future of cancer...
- Pipeline
Pipeline - SOTIO®
- Clinical trials
Clinical trials - SOTIO®
- News & Publications
SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO...
- IL-15 Superagonist
IL-15 Superagonist - SOTIO®
- Antibody-Drug Conjugates
Antibody-Drug Conjugates - SOTIO®
- Cell Therapies
Cell Therapies - SOTIO®
- Science
Science - SOTIO®
- About us
SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, ...
SOTIO Biotech. 8,314 followers. 3w. Last month marked our team’s seventh year participating in the “Do práce na kole” ( #BiketoWork) challenge in #Prague, where many of our colleagues are ...
Cytune Pharma is a French biotechnology company researching and developing new therapies designed to strengthen the immune response of patients suffering from cancer and infectious diseases. It is member of the SOTIO Biotech group, which develops Interleukin-15-based products based on research of Cytune Pharma. Autolus Therapeutics
SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of cancer and has facilities in Europe and the US.
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. The robust SOTIO clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, SOT101, currently being tested in phase II clinical trials.
People also ask
What is Soto biotech?
Who is the CEO of Soto biotech?
How many followers does Soto biotech have?
Is Soto a safe & effective treatment for solid tumours?
Connect. Transposon Therapeutics, Inc. is developing TPN-101 (also known as Censavudine) and other LINE-1 reverse transcriptase inhibitors for the treatment of rare neurodegenerative diseases such as progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Aicardi-Goutières Syndrome (AGS).
